MarketPulse
L

$LSTA

5 articles found
0 positive
3 negative
2 neutral
GlobeNewswire Inc.GlobeNewswire Inc.··Brodsky & Smith

Law Firm Probes Four M&A Deals Over Fiduciary Duty Concerns

Brodsky & Smith investigates four merger transactions, questioning whether boards ensured fair shareholder value in acquisitions valued at $3.16 to $35.00 per share.
ESPRSKYTLSTASILAshareholder rightsacquisition
GlobeNewswire Inc.GlobeNewswire Inc.··Halper Sadeh Llc

Investor Rights Firm Scrutinizes $30+ SILA Deal and LSTA Acquisition for Fairness

Halper Sadeh investigates whether Sila Realty and Lisata Therapeutics shareholders are receiving fair consideration in proposed acquisitions by Blue Owl and Kuva Labs.
LSTASILAfiduciary dutysecurities law
GlobeNewswire Inc.GlobeNewswire Inc.··Juan Monteverde

Major M&A Deals Face Legal Scrutiny as Class Action Firm Launches Shareholder Inquiries

Monteverde & Associates launches class action investigations into three major M&A deals: Lisata-Smithfield, Independent Bank-HCB Financial, and Sila Realty-Sunshine Ultimate. Seeking potentially affected shareholders.
LSTAIBCPHCBNSILAclass actionsecurities litigation
BenzingaBenzinga··Globe Newswire

Lisata Therapeutics to Be Acquired by Kuva Labs for $5 Per Share Plus Contingent Payments

Lisata Therapeutics agreed to be acquired by Kuva Labs for $5.00 per share plus up to $1.00 contingent payment, closing expected in Q2 2026.
LSTAacquisitionFDA approval
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Lisata Therapeutics to Be Acquired by Kuva Labs for $5 Per Share Plus Milestone Payment

Lisata Therapeutics agrees to be acquired by Kuva Labs for $5 per share plus up to $1 contingent payment tied to FDA approval, with close expected in Q2 2026.
LSTAacquisitionFDA approval